Evidence map›Paper›PMID 40442467›Full record

ReviewHandbook of experimental pharmacology2025

The Road Toward Nanopore Sequencing of Glycosaminoglycans.

Wesley Pietsch, Tom Schumann, Marc Safferthal, Niklas Geue, Kevin Pagel, Michael Götze

Abstract readReview
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Automating Model Building for SPM Images of Biomolecules Using MISO.Journal of chemical information and modeling · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wesley PietschInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Tom SchumannInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Marc SafferthalInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Niklas GeueInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Kevin PagelInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Michael GötzeInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. m.goetze@fu-berlin.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanopores have emerged as a powerful, label-free technique for single molecule analysis, offering high sensitivity and rapid analysis capabilities. Originally developed for DNA sequencing, nanopores have shown promise not only for the characterization of other biomolecules, such as RNA, proteins, and glycans but also of small inorganic compounds, such as nanoparticles. Glycosaminoglycans (GAGs) are a linear, highly charged subclass of glycans, which play essential roles in cell signaling, tissue development, and inflammation processes. The immense structural complexity of GAGs involving unique sulfation patterns renders their analysis challenging. This chapter provides a comprehensive overview on the application of biological and solid-state nanopores for the analysis of GAGs.

Indexed as

GlycosaminoglycansNanoporesNanopore SequencingAnimalsHumansGlycosaminoglycansBiological nanoporesCarbohydratesMolecule translocationSequencingSolid-state nanopores

Identifiers

PMID40442467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.